Clinical Trials on Autosomal Recessive Polycystic Kidney Disease

Total 13198 results

Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)

United States, United Kingdom, Belgium, Poland, France, Germany, Italy
Kadmon Corporation, LLC

Completed

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Polycystic Kidney, Autosomal Recessive

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
Emory University
PKD Foundation

Completed

ADPKD Cohort Study

Autosomal Dominant Polycystic Kidney Disease

United States
Mario Negri Institute for Pharmacological Research
Otsuka Pharmaceutical Italy S.r.l.

Completed

Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL)

Autosomal Dominant Polycystic Kidney Disease

Italy
CHU de Reims

Completed

ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure? (PDP-ADPKD)

Autosomal Dominant Polycystic Kidney Disease

France
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Regional Hospital Holstebro
Aarhus University Hospital

Completed

Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TOPO)

Autosomal Dominant Polycystic Kidney Disease

Denmark
University Hospital, Brest

Unknown

Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease) (GENKYST)

Autosomal Dominant Polycystic Kidney Disease

France
Federico II University

Completed

Effects of Somatostatin on Liver in ADPKD

Autosomal Dominant Polycystic Kidney Disease
University of North Carolina, Chapel Hill
National Institute of General Medical Sciences (NIGMS)

Completed

ADPKD Alterations in Hepatic Transporter Function

Renal Disease | Autosomal Dominant Polycystic Kidney Disease | ADPKD

United States
Kadmon Corporation, LLC

Terminated

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Kyorin University

Unknown

Efficacy of Tolvaptan on ADPKD Patients

Autosomal Dominant Polycystic Kidney Disease

Japan
Assistance Publique - Hôpitaux de Paris
IPSEN pharmaceutical company, Boulogne-Billancourt, France

Completed

Lanreotide In Polycystic Kidney Disease Study (LIPS)

Autosomal Dominant Polycystic Kidney Disease (ADPKD

France
Cambridge University Hospitals NHS Foundation Trust
Addenbrookes Charitable Trust; PKD Charity; British Renal Society & British Kidney...

Completed

High Water Intake in Polycystic Kidney Disease (DRINK)

Autosomal Dominant Polycystic Kidney Disease

United Kingdom
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP II)

Autosomal Dominant Polycystic Kidney Disease

United States
Andreas L. Serra

Unknown

The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe

Autosomal Dominant Polycystic Kidney Disease

France, Switzerland, Germany, Netherlands, Belgium, Czech Republic, Italy, Spain, Turkey, United Kingdom
University Medical Center Groningen
Radboud University Medical Center; Erasmus Medical Center; Leiden University...

Unknown

Study of Lanreotide to Treat Polycystic Kidney Disease (DIPAK1)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Netherlands
Mario Negri Institute for Pharmacological Research

Completed

Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study (ALADIN)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Italy
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ALERT)

ADPKD | Polycystic Kidney Disease, Adult

United States
Tufts Medical Center

Completed

Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Otsuka Pharmaceutical Europe Ltd

Unknown

A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe (ACQUIRE)

Autosomal Dominant Polycystic Kidney Disease

Spain, United Kingdom, Germany, France, Belgium, Switzerland, Austria
Federico II University

Completed

Effects of Somatostatin on ADPKD Heart

Autosomal Dominant Polycystic Kidney Disease | Glomerular Filtration Rate > 40 ml/Min
CHU de Reims

Completed

Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). (ADPKDPD)

Polycystic Kidney Diseases

France
Vertex Pharmaceuticals Incorporated

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
The University of Queensland

Recruiting

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

Autosomal Dominant Polycystic Kidney Disease

Australia
Mayo Clinic
Polycystic Kidney Disease Foundation

Recruiting

NOX4 and Related Biomarkers in ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
University of Cologne

Recruiting

The German ADPKD Tolvaptan Treatment Registry (AD(H)PKD)

ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Germany
Regulus Therapeutics Inc.

Completed

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney Disease, Autosomal Dominant

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany
University of Zurich

Completed

Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Switzerland
Istanbul University

Completed

Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Turkey
AceLink Therapeutics, Inc.
Novotech (Australia) Pty Limited

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers

Autosomal Dominant Polycystic Kidney

Australia
Children's National Research Institute

Recruiting

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study (ADPKD)

ADPKD

United States
Indiana University

Completed

Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease (PIOPKD)

Polycystic Kidney Disease

United States
The Cleveland Clinic
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Polycystic Kidney Diseases

United States
Zhi-Hong Liu, M.D.

Terminated

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney

China
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD (HCY)

Autosomal Dominant Polycystic Kidney Disease

United States
University of Chicago

Withdrawn

The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain

Autosomal Dominant Polycystic Kidney Disease
Mayo Clinic

Completed

New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease (MRI Pilot)

Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease (OVERTURE)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Italy, Japan, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Mario Negri Institute for Pharmacological Research

Terminated

Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency (SIRENA-II)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Italy
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Intrarenal Microvasculature in ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Mayo Clinic
University of Kansas Medical Center

Completed

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease (ESSENTIAL)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Netherlands
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Autosomal Dominant Polycystic Kidney Disease

Japan
Kyorin University
Otsuka Pharmaceutical Co., Ltd.

Completed

Clinical Implications of DNA Analysis on ADPKD (DNAAA)

Autosomal Dominant Polycystic Kidney Disease

Japan
University of Kansas

Completed

A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

United States
University of Kansas

Completed

Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

United States

Clinical Trials on Autosomal Recessive Polycystic Kidney Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations